Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 11/20 | 0.45 |
| ▸ | HPRT1 | P00492 | 5/20 | 0.44 |
| ▸ | NT5E | P21589 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13082345 | 0.86 | PNP (0.51) | PNPHPRT1POLB | |
| SCHEMBL12151598 | 0.82 | HPRT1 (0.61) | PNPHPRT1NT5EPOLBFUT5 | |
| SCHEMBL3759846 | 0.82 | HPRT1 (0.61) | PNPHPRT1NT5EPOLBFUT5 | |
| SCHEMBL12154664 | 0.82 | HPRT1 (0.61) | PNPHPRT1NT5EPOLBFUT5 | |
| SCHEMBL13057657 | 0.80 | TLR7 (0.36) | PNPTLR7FUT5 | |
| SCHEMBL13057646 | 0.78 | AHCY (0.45) | NT5EPOLB | |
| SCHEMBL3761353 | 0.78 | AHCY (0.45) | NT5EPOLB | |
| SCHEMBL12300446 | 0.78 | HPRT1 (0.43) | PNPHPRT1NT5EPOLBTLR7 | |
| SCHEMBL3313805 | 0.78 | PNP (0.40) | PNPHPRT1NT5EPOLBTLR7 | |
| SCHEMBL13396453 | 0.78 | PNP (0.40) | PNPHPRT1NT5EPOLBTLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842672-B2 | Phosphonate inhibitors of HCV | GILEAD SCIENCES, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20080107628-A1 | Polymerase inhibitors | GILEAD SCIENCES, INC. | 2008-05-08 | — | — | US | disclosed |
| WO-2008005542-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC., (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080107628-A1 | Polymerase inhibitors | POLR2H, POLR2E, POLR1E | PNP 80/4885HPRT1 529/4885NT5E 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.